

Ministry of Health

Ontario COVID-19 Vaccine Update

Primary Care COVID-19 Discussion Table

October 14, 2022

Agenda

1. Provincial Dashboard
2. Fall Boosters
3. Priority Populations and Immunocompromised Individuals
4. Children 5-11 years Coverage
5. Children 0-4 Years Coverage
6. Inventory Status
7. Next Steps

NACI Fall Booster Recommendations (June 2022)



Strong Recommendation for High Risk

NACI strongly recommends a booster dose for all adults, and for adolescents who are at high risk for severe disease.



Booster in Advance of Future Wave

Fall booster doses in advance of a potential future wave of COVID-19 is most important for populations at increased risk of severe COVID-19 disease.




Protection Wanes Over Time

Evidence to date suggests that while protection against symptomatic disease wanes over time, protection against severe disease is better maintained.

Flow Diagram for COVID-19 Booster Vaccination – When should you get a booster dose?

For individuals aged 5 and older who have completed a primary series: Use the chart below to determine when it's time to get your COVID-19 booster.



- Health care workers are not at a higher risk of severe outcomes, unless they belong to another high-risk group. However, health care workers who care for high-risk patients are recommended to be vaccinated to protect their vulnerable patients and all health care workers are recommended to be vaccinated to ensure health system capacity.
- All vaccines available in Ontario are approved by Health Canada and are safe, effective, and are the best way to stay protected from COVID-19 and its variants.
- Bivalent Omicron-containing mRNA COVID-19 vaccines are the preferred booster products for authorized age groups (i.e., individuals 12 and older).

Provincial Dashboard - As of October 12, 2022

Doses Administered

35,598,737

Total Shots in Arms

33,311

Shots in Arms Yesterday

4,801

Shots in Arms Previous Day

Daily Doses (7-day average)

25,531

Daily Doses

491

Daily Dose 1

631

Daily Dose 2

24,409

Daily Booster Doses

Population Coverage

12,799,242

People w/ at least 1 dose

+ 607 from previous day

93.9%

% of pop 18+

91.0%

% of pop 5+

86.9%

% of total pop

12,313,159

People completed primary series

+ 660 from previous

91.7%

% of pop 18+

87.8%

% of pop 5+

83.6%

% of total pop

756,301

People vaccinated w/Fall Booster*

+ 32,013 from previous day

6.0%

% of pop 18+

5.4%

% of pop 5+

5.1%

% of total pop

Federal Allocation

36,374,591

(Received to date)

Pfizer Received= 23,340,241

Administered= 23,521,333

Moderna Received= 11,826,050

Administered= 9,576,418

Astra/CV Received= 1,168,300

Administered= 1,087,700


Janssen Received= 10,000

Administered= 3,909

Novavax Received=30,000

Administered= 11,484

Trending: Doses Administered Week by Week




Current Week

	Total	1st	2nd	3rd	4th	5th
	n	n	n	n	n	n
Sun	6,766	188	369	543	3,936	1,730
Mon	4,801	125	108	300	2,733	1,535
Tue	33,311	607	661	1,351	15,649	15,043

*Vaccinated with Fall Booster dose - individuals who have completed their primary series

5+ Fall Booster Coverage as of October 10, 2022



Key Insights


- Fall booster coverage for 5+ in Ontario is **5.2%** and coverage by age is:
 - 70+: **15%**
 - 50-69: **6%**
 - 18-49: **3%**
 - 12-17: **1%**
 - 5-11: **3%**
- Fall booster coverage for 70+ across PHUs ranges from **8%** to **24%**
- PHUs have been organized in descending order based on 70+ coverage rates

Vaccinated with Fall Booster: Completed primary series and received a booster on or after September 1, 2022

Data Source(s): SAS VA Tool, COVax analytical file, extracted daily at 8:00 pm, CPAD, MOH. Note: analytical file has been processed for data quality checks and results may differ from the COVax live data system. Population Estimates 2020, Statistics Canada, CCM Cases Data, OLIS Testing File, CCSO ICU File



Children 5-11 Years: Coverage as of October 10, 2022



Key Insights


- Provincial coverage for children 5-11:
 - At least 1 dose: **59%**
 - Completed primary series: **39%**
- About **211K** children 5-11 with a 1st dose are yet to get a 2nd dose
- About **389K** children 5-11 with 2nd dose are yet to get a 3rd dose
- PHUs are arranged by 5-11 “at least 1 dose coverage” as of Oct 10 from highest to lowest

Completed primary series – includes individuals who have received:

- * one dose of a single-dose vaccine series (e.g., Janssen), where the vaccine is Health Canada approved, or
- * both doses of a two-dose vaccine series, where at least one of the products are Health Canada approved. This includes individuals who received two doses of the same vaccine, or individuals who had mixed doses (for example, one AstraZeneca and one Pfizer), or
- * three doses of any vaccine product, whether the vaccine(s) are Health Canada approved or not,

Data Source(s): SAS VA Tool, COVax analytical file, extracted daily at 8:00 pm, CPAD, MOH. Note: analytical file has been processed for data quality checks and results may differ from the COVax live data system. Population Estimates 2020, Statistics Canada, CCM Cases Data, OLIS Testing File, CCSO ICU File

Children 0-4 Years: First Dose Coverage Growth Oct 2 - 10, 2022



Key Insights

- Coverage for children 0-4 years in Ontario is **6.2%** as of Oct 10, with an **increase of 0.2%** since Oct 2
 - Coverage increase for PHUs ranges between **0.03%** to **0.5%**
- PHUs are arranged by 0-4 1st dose coverage as of Oct 10 from highest to lowest

Data Source(s): SAS VA Tool, COVax analytical file, extracted daily at 8:00 pm, CPAD, MOH. Note: analytical file has been processed for data quality checks and results may differ from the COVax live data system. Population Estimates 2020, Statistics Canada, CCM Cases Data, OLIS Testing File, CCSO ICU File

COVID 19 Vaccine Inventory Supply Update

- Bivalent Vaccine
 - Moderna Bivalent for 18+ years – September 12, 2022
 - Pfizer Bivalent for 12+ years – starting week of October 17
 -
- Infant Vaccine
 - Moderna Infant vaccine (2 doses) – approved July 2022
 - Infant Pfizer vaccine (3 doses) – approved and available in Sept 2022

Next Steps

- Continue to recommend that patients get vaccinated as part of the Fall Booster Campaign
 - High-risk patients should be vaccinated at the minimum 3 month interval before respiratory illness season with new bivalent vaccine
- Continue to recommend to parents and caregivers the importance of having children stay up to date with routine immunization, including COVID-19
- MOH to continue to work with ICES to update reporting for high risk and priority populations for Fall Booster vaccine uptake

Appendix

COVID-19 Vaccines for Children and Youth (Fall 2022)

1 st Dose – Primary Series	2 nd Dose – Primary Series	3 rd Dose – Primary Series	Fall 2022 Booster Dose
6 MONTHS–4 YEARS			
Up to Date: After completion of primary series, since a booster is not authorized for this age group at this time			
Pfizer-BioNTech (3 mcg/0.2mL)	Pfizer-BioNTech (3 mcg/0.2mL) 2 months (56 days) since 1 st dose	Pfizer-BioNTech (3 mcg/0.2mL) 2 months (56 days) since 2 nd dose	No booster dose is authorized for this age group
Moderna (25 mcg)	Moderna (25 mcg/0.25mL) 2 months (56 days) since 1 st dose	Moderna (25 mcg/0.25mL) 2 months (56 days) since 2 nd dose *ONLY FOR IC	
5-11 YEARS			
Up to Date: Completed the primary series and have received a COVID-19 vaccine within the last 6 months			
Pfizer-BioNTech (10 mcg/0.2mL)	Pfizer-BioNTech (10 mcg/0.2mL) 2 months (56 days) since 1 st dose	Pfizer-BioNTech (10 mcg/0.2mL) 2 months (56 days) since 2 nd dose *ONLY FOR IC	Pfizer-BioNTech (10 mcg/0.2mL) 6 months (168 days) since last dose
12-17 YEARS			
Up to Date: Completed the primary series and have received a COVID-19 vaccine within the last 6 months			
Pfizer-BioNTech (30 mcg/0.3mL)	Pfizer-BioNTech (30 mcg/0.3mL) 2 months (56 days) since 1 st dose	Pfizer-BioNTech (30 mcg/0.3mL) 2 months (56 days) since 2 nd dose *ONLY FOR IC	Bivalent Pfizer-BioNTech (30 mcg/0.3mL) 6 months (168 days) after last dose OR 3 months (84 days) for high-risk groups

IC = Immunocompromised

High Risk Groups: Aged 65 or older • First Nations, Inuit, or Métis individual or household member aged 18 and older • Resident of LTC, RH, or other CC setting • Pregnant individuals • Moderately to severely Immunocompromised aged 12 or older • Health Care Worker aged 18 and older

COVID-19 Vaccines for 18+ (Fall 2022)

1 st Dose – Primary Series	2 nd Dose – Primary Series	3 rd Dose – Primary Series	Fall 2022 Booster Dose
18 YEARS and OLDER			
Up to Date: Completed the primary series and have received a COVID-19 vaccine within the last 6 months			
Pfizer-BioNTech (30 mcg/0.3mL) *PREFERRED VACCINE FOR AGES 18-29	Pfizer-BioNTech (30 mcg/0.3mL) 2 months (56 days) after 1 st dose *PREFERRED VACCINE FOR AGES 18-29	Pfizer-BioNTech (30 mcg/0.3mL) 2 months (56 days) after 2 nd dose *ONLY FOR IC	Bivalent Pfizer-BioNTech (30 mcg/0.3mL) 6 months (168 days) after last dose OR 3 months (84 days) for high-risk groups
Moderna (100mcg/0.5mL)	Moderna (100mcg/0.5mL) 2 months (56 days) after 1 st dose	Moderna (100mcg/0.5mL) 2 months (56 days) after 2 nd dose *ONLY FOR IC	Bivalent Moderna (50 mcg/0.5mL) 6 months (168 days) after last dose OR 3 months (84 days) for high-risk groups
Novovax may be offered to individuals in the authorized age group (18 years and older) without contraindications to the vaccine who are not able or willing to receive an mRNA COVID-19 vaccine.			
Janssen may be offered to individuals who are 18 years and older without contraindications to the vaccine, only when all other authorized COVID-19 vaccines are contraindicated.			

IC = Immunocompromised

High Risk Groups: Aged 65 or older • First Nations, Inuit, or Métis individual or household member aged 18 and older • Resident of LTC, RH, or other CC setting • Pregnant individuals • Moderately to severely Immunocompromised aged 12 or older • Health Care Worker aged 18 and older

Bivalent vs Monovalent (Boosters) Administration by Age Group as of Oct 5, 2022

Ontario


Bivalent Doses Administered
591,531

Bivalent Doses Administered Yesterday
4,206


Bivalent Doses Administered (60+)
382,946

Bivalent Doses Administered Yesterday (60+)
1,973


WEEK BY WEEK



BY AGE GROUP




BY PHU OF VACCINE EVENT (AGE 60+)



Provincial Overview: Priority Populations

As of August 28, 2022




Note:

* Immunocompromised population includes individuals under the categories of: *Other treatment causing immunosuppression, Hematological Malignancy, Chronic Kidney Disease (with recent receipt of dialysis), Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Other immunocompromising health conditions*

Data Sources:

Chung H, Fung K, Ishiguro L, Paterson M, et al. Characteristics of COVID-19 diagnostic test recipients, Applied Health Research Questions (AHRQ) # 2021 0950 080 000. Toronto: Institute for Clinical Evaluative Sciences; 2020.

Provincial Overview: Vaccine Coverage Increase for Priority Populations (0+) between July 31 and August 28, 2022



■ At least 2 doses coverage as of Jul 31
 ■ At least 3 doses coverage as of Jul 31
 ■ 4 doses coverage as of Jul 31
 ■ Coverage increase Jul 31 - Aug 28

Data Sources:


Chung H, Fung K, Ishiguro L, Paterson M, et al. Characteristics of COVID-19 diagnostic test recipients, Applied Health Research Questions (AHRQ) # 2021 0950 080 000. Toronto: Institute for Clinical Evaluative Sciences; 2020.

Notes:

- Categories have been divided into 2 sections (Immunocompromised & non-immunocompromised) and each section is ordered by 1st dose coverage from highest to lowest
- Immunocompromised * category is an aggregation of the 6 groups below it

Immunocompromised Populations

Fall Boosters: Delivery Channel Proportions for September 2022




Key Insights

- PHUs are ordered by actual proportion in pharmacy for September from highest to lowest
- Higher proportion of doses administered in **PHU-led clinics** compared to what PHUs had planned (**44% vs 37%**)
- Lower proportion of doses administered through Pharmacy compared to what PHUs had planned (**45% vs 51%**)

Data Source(s):

1. SAS VA Tool, COVax analytical file, extracted daily at 8:00 pm, CPAD, MOH. Note: analytical file has been processed for data quality checks and results may differ from the COVax live data system. Population Estimates 2020, Statistics Canada, CCM Cases Data, OLIS Testing File, CCSO ICU File
2. PHU COVID-19 Surge Planning Survey, August 14, 2022 Ontario Ministry of Health

Children 0-4 Years: Delivery Channels Between October 1-10, 2022



Key Insights

- 85% of doses were administered in PHU led clinics (MIC + Clinics + Mobile)
- Breakdown for other channels:
 - Primary Care: 4%
 - Pharmacy: 8%
 - Hospital-based: 2%
- Top 5 PHUs using Primary Care:
 - Windsor-Essex (35%)
 - Peel (35%)
 - WDG (35%)
 - Timiskaming (31%)
 - LGL (21%)
- Note: PHUs are ordered by under 5 first dose coverage from highest to lowest

Data Source(s): SAS VA Tool, COVax analytical file, extracted daily at 8:00 pm, CPAD, MOH. Note: analytical file has been processed for data quality checks and results may differ from the COVax live data system. Population Estimates 2020, Statistics Canada, CCM Cases Data, OLIS Testing File, CCSO ICU File

Delivery Channel Breakdown

Delivery Channel (SAS VA)	Vaccine Event Type (COVax)
MICs	Mass Immunization Clinic
	Mass Immunization Clinic – Drive Through
Clinics	Pop-up Clinics
	School-based clinics
	Indigenous clinics
	Workplace clinics
	Other
Mobile	Mobile Delivery Site
	Mobile Team – Home Bound Patients
Primary Care Settings	Primary Care / Physician’s Office
Hospital-based Clinic	Hospital-based Clinic
Pharmacy	Pharmacy
Congregate Care	Long Term Care Home
	Retirement Home
	Assisted Living Facility
	Other Congregate Care Setting

Vaccination Status Definitions

Vaccination Status	Description
At least one dose	Number of individuals who have received at least one COVID-19 vaccine dose (i.e., they could have one, two or three doses). Includes individuals that are partially or fully vaccinated.
Completed primary series	Includes individuals who have received: <ul style="list-style-type: none"> • one dose of a single-dose vaccine series (e.g., Janssen), where the vaccine is Health Canada approved, or • both doses of a two-dose vaccine series, where at least one of the products are Health Canada approved. This includes individuals who received two doses of the same vaccine, or individuals who had mixed doses (for example, one AstraZeneca and one Pfizer), or • three doses of any vaccine product, whether the vaccine(s) are Health Canada approved or not
Vaccinated with booster doses	Individuals who have received three plus doses of Health Canada approved vaccines.
Vaccinated with fall booster doses	Individuals who have completed their primary series and received a booster dose on/after September 1, 2022. This group is a subset of those completed primary series.